|3.22 -0.01 (-0.31%)||12-01 15:59|
|Targets||6-month :||4.21||1-year :||4.66|
|Resists||First :||3.6||Second :||3.99|
|Supports||First :||2.99||Second :||2.48|
|MAs||MA(5) :||3.15||MA(20) :||3.47|
|MA(100) :||3.16||MA(250) :||3.54|
|MACD||MACD :||-0.1||Signal :||-0.1|
|%K %D||K(14,3) :||20.9||D(3) :||12.3|
|52-week||High :||9.01||Low :||1.86|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BNTC ] has closed above bottom band by 37.7%. Bollinger Bands are 3.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||3.47 - 3.49||3.49 - 3.5|
|Low:||3.02 - 3.04||3.04 - 3.06|
|Close:||3.15 - 3.18||3.18 - 3.21|
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||0 (M)|
|Shares Float||3 (M)|
|Held by Insiders||2e+006 (%)|
|Held by Institutions||0 (%)|
|Shares Short||68 (K)|
|Shares Short P.Month||0 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0|
|Profit Margin||0 %|
|Operating Margin||-27 %|
|Return on Assets (ttm)||166.6 %|
|Return on Equity (ttm)||-56.4 %|
|Qtrly Rev. Growth||75000 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||-112.89|
|Qtrly Earnings Growth||-234.9 %|
|Operating Cash Flow||0 (M)|
|Levered Free Cash Flow||-19 (M)|
|Price to Book value||0|
|Price to Sales||-0.03|
|Price to Cash Flow||0.36|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|